CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia - Wikidata - wikimedia - TriplyDB

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q29620607

about

Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors Clinical development of gene therapy: results and lessons from recent successes Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy Clinical manufacturing of CAR T cells: foundation of a promising therapy Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Tailoring the Treatment of Melanoma: Implications for Personalized Medicine Novel immunotherapies in lymphoid malignancies Adoptive T-Cell Immunotherapy CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Potentiality of immunotherapy against hepatocellular carcinoma Trial Watch: Adoptive cell transfer for oncological indications Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia Immunotherapy of Childhood Sarcomas Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Immune Modulation in Hematologic Malignancies Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Progress and prospects for engineered T cell therapies Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies The next steps in next-gen sequencing of cancer genomes Novel immunotherapies for hematologic malignancies Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia Adoptive T-cell therapy for Leukemia Using gene therapy to manipulate the immune system in the fight against B-cell leukemias Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab CD4 T-cell immunotherapy for chronic viral infections and cancer Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.High-content molecular profiling of T-cell therapy in oncology Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy

P2860

Q26741260-53082A67-7556-4334-B7DC-41FE2611907E Q26743393-DC542922-5AF6-41E4-AEDD-769838C96FC1 Q26744654-7DBC2DFD-FABC-45F8-AEBD-F34E85219BE9 Q26747037-93AD1FE3-8689-43DA-B417-97FD934A8229 Q26751020-E68B7B2F-8989-49AB-BCED-831F8FE48FD3 Q26753082-FFDF56FA-F018-4497-A9D5-C1D3173435B9 Q26767514-BEDE50A9-E4AF-4A77-81CC-3BD1E0BA0D92 Q26768154-258D53C4-C365-478E-873C-775789A43AFB Q26772315-909339CA-F867-46B1-BDC9-68580E5F2025 Q26773309-B8AD8373-7DE8-46C2-A4E1-53973731E449 Q26775720-C81A3AB1-658A-45FC-8DE5-424EB7DC22BE Q26775806-B126DCC8-73B8-490B-826C-85CBBFA90A71 Q26777394-FA5DAB7B-A7D1-4AEE-A506-5D6284EA81F2 Q26782845-1710D2E5-F8CF-4FC6-B7F6-F25D2BEF583F Q26783433-472FEEB9-33E6-4EE3-AB91-991C5FC26DC4 Q26784228-05E76A7C-91DE-4430-A69F-780CE7AE4AC5 Q26785545-B34D949A-AB6C-4D28-9980-CBDA57F5D1FB Q26785828-ED229478-2FF2-4593-8806-91955194FBC7 Q26795369-C27CD263-3225-40E6-AB42-FA2FD358B513 Q26795540-EB8B0F02-B011-4FB4-BA46-6EB0CC6D53F9 Q26796307-20D6D787-0491-448D-8B12-C9991CD5B70D Q26798404-E4CA0E17-23E7-40E6-BD6C-F23905DA1F50 Q26826830-6FAFBA12-3A99-4F07-AA4A-EC5A2A24B746 Q26852923-6B45233A-DC08-4F4D-9DF9-A91BF28F2E2D Q26865838-AA3E0E82-35CC-4155-8144-463379DA4082 Q26998894-DAA1E238-C93C-49E0-A0DE-3B486E2A04ED Q27004436-5CD4D11C-147F-4EBB-B7DF-DA115CF29ED4 Q27006773-93FC8D36-96B6-4B4F-B23F-32D22544D6EA Q27006934-109F2C26-FFD9-44F4-A35B-59C52FCFCCA4 Q27011297-6D2E5E94-6BEF-4F45-AA5A-31F919319166 Q27013710-FE59A1BB-0596-4721-A507-64C451D341EC Q27022957-559724E7-F94E-4864-B8BA-8839F11D892E Q27025300-D26219A6-6D87-448C-B345-F701D5239EDB Q27313856-4EDFF989-582E-446F-B6FF-CFF801109875 Q27318470-522F5CD9-2E06-49B8-B8E5-8E3F7B715DEE Q27334215-7872401A-F8DC-4E28-9C80-B4F07ADDA811 Q27345402-0C83FD98-E5B8-4823-9E37-9750B40968ED Q28066792-969A9DE5-F0B9-4A90-AAA9-204D305A76C5 Q28067102-A270EEAC-5683-44E1-A7C1-F9D0260C8EB1 Q28073563-CB714242-C8D1-4456-AD60-0476BCDB60D4

P2860

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q29620607

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

CD19-targeted T cells rapidly ...... y acute lymphoblastic leukemia

@ast

CD19-targeted T cells rapidly ...... y acute lymphoblastic leukemia

@en

type

label

CD19-targeted T cells rapidly ...... y acute lymphoblastic leukemia

@ast

CD19-targeted T cells rapidly ...... y acute lymphoblastic leukemia

@en

prefLabel

CD19-targeted T cells rapidly ...... y acute lymphoblastic leukemia

@ast

CD19-targeted T cells rapidly ...... y acute lymphoblastic leukemia

@en

P1433

Q29620607-4FBD56C4-1289-4F86-9D7B-856449A447CD

P1476

Q29620607-B26B79E9-4496-4F44-BCF1-43954B7510E5

P2093

Q29620607-1B0DBECD-963F-4308-809B-B283B493E733

Q29620607-23FFC292-648C-4554-867F-D66F2CC9B397

Q29620607-275B2324-706F-4B7F-891A-33F289A79300

Q29620607-2FCB8CC9-8597-40EB-9D5C-21FCC9E7BF7A

Q29620607-34D65AEC-2EFA-43C0-A21B-A2B404424460

Q29620607-4759DC3C-75B9-4F0F-A785-8EC6DF571BEE

Q29620607-49073CF8-FAF8-4974-9C38-F63DCCB515FC

Q29620607-63986CBE-F6E7-4F59-9912-4A1AFE1AC470

Q29620607-6835B3C2-1129-4351-8285-0C22DB3985FF

Q29620607-7065F21B-60A4-4EF7-920B-7FA7C410B08E

P2860

Q29620607-19BF780B-1704-4EDA-AD94-591713512A0D

Q29620607-23DFBA90-DBB5-4CF7-842D-14C16521BAEE

Q29620607-247C01D2-4186-4BB8-A6F4-6FEA9FC63E44

Q29620607-2974D7CD-0D0B-417C-8204-87406EBF20F5

Q29620607-36C5B22F-B063-43D6-88DF-E7978898F162

Q29620607-46547FF1-505B-4708-A12B-6B9B59EA24A1

Q29620607-46CC45FE-CCED-4127-8F14-FF21A9D8022F

Q29620607-5E5664A4-597C-436A-B02E-53574BC12BEF

Q29620607-5F0B23BE-0E9D-47BE-BF1E-082C9D9F8F95

Q29620607-621E6B46-0F0D-45A3-BFE6-4FA6C4F44142

P304

Q29620607-CAB9E3AA-9B77-4201-9AE6-904875B1E324

P31

Q29620607-8D59CC50-BEAB-40F0-B5D9-5EA13D1D9066

P3181

Q29620607-2A918159-373F-4EE3-AC37-169F36A62E95

P356

Q29620607-8CFAEA6D-2DC4-4D64-ADF6-D1BE77C42829

P407

Q29620607-067672AB-E603-4619-8FD0-DE69CD24424B

P433

Q29620607-F931B0F5-1F41-424C-A179-349D866A09BC

P478

Q29620607-511C17CA-1054-4107-8D58-C91FAA732C04

P577

Q29620607-A5889699-952C-4286-9652-2B9693724B29

P5875

Q29620607-12B32876-F9ED-421C-AE7C-44B21E937B92

P698

Q29620607-CA3A63F4-C667-4B83-91A3-17CA2C284448

P921

Q29620607-DE91AB38-4393-49E6-8DAB-560E7160FE70

Q29620607-F87EE51A-36BB-4351-8163-EA39F22FC8CD

P932

Q29620607-47AED3ED-3B52-4253-B47E-A67BA9A49F75

P3181

P356

SCITRANSLMED.3005930

P1433

Science Translational Medicine

P1476

CD19-targeted T cells rapidly ...... y acute lymphoblastic leukemia

@en

P2093

Bartido S

http://www.w3.org/2001/XMLSchema#string

Bernal Y

http://www.w3.org/2001/XMLSchema#string

Borquez-Ojeda O

http://www.w3.org/2001/XMLSchema#string

Brentjens RJ

http://www.w3.org/2001/XMLSchema#string

Cowell LG

http://www.w3.org/2001/XMLSchema#string

Curran K

http://www.w3.org/2001/XMLSchema#string

Davila ML

http://www.w3.org/2001/XMLSchema#string

Frattini M

http://www.w3.org/2001/XMLSchema#string

He Q

http://www.w3.org/2001/XMLSchema#string

Hedvat C

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

How do CARs work?: Early insights from recent clinical studies targeting CD19.

P304

177ra38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1288229

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCITRANSLMED.3005930

http://www.w3.org/2001/XMLSchema#string

P407

P433

177

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236067161

http://www.w3.org/2001/XMLSchema#string

P698

23515080

http://www.w3.org/2001/XMLSchema#string

P921

P932

3742551

http://www.w3.org/2001/XMLSchema#string